Administration of isoproterenol and adenosine to guide supplemental ablation after pulmonary vein antrum isolation

J Cardiovasc Electrophysiol. 2013 Nov;24(11):1199-206. doi: 10.1111/jce.12252. Epub 2013 Sep 10.

Abstract

Background: Pulmonary vein antrum isolation (PVAI) remains associated with atrial fibrillation (AF) recurrence. We administered adenosine and isoproterenol (ISP) after PVAI to uncover non-PV atrial triggers and PV reconnection, potentially increasing ablation success rate.

Methods: One hundred and ninety-two consecutive patients with symptomatic AF presenting for PVAI were prospectively studied (group 1). Following PVAI, adenosine (18-24 mg) and ISP (20-30 mcg/min) were administered intravenously. Supplemental ablation was performed in patients with non-PV triggers that induced AF (group 1A). Other subgroups included patients with (group 1B) or without (group 1C) consistent non-PV atrial foci that did not induce AF. A cohort of 196 matched control patients undergoing PVAI without drug challenge was used for comparison (group 2).

Results: A total of 132 atrial non-PV foci were revealed (31 inducing AF). The majority of atrial foci were observed with ISP (113/132, 86%). Less than 5% of patients had persistent PV recovery during the drug challenge. During a mean follow-up of 22 ± 8 months, PVAI was successful in 110/192 (57%, group 1) versus 100/196 (52%, group 2), P = 0.038. Furthermore, the success rate was statistically different between group 1A (25/32, 78%), group 1B (28/83, 34%), and group 1C (57/74, 74%), P < 0.001.

Conclusion: After PVAI, ablation guided by the administration of adenosine and ISP to target non-PV triggers inducing AF increased AF ablation outcomes. Patients with non-PV foci that did not induce AF had no further ablation, with the lowest ablation success rate. This group may likely benefit from further ablation after PVAI.

Keywords: adenosine; atrial fibrillation; catheter ablation; isoproterenol; pulmonary vein isolation.

Publication types

  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adenosine* / administration & dosage
  • Aged
  • Atrial Fibrillation / diagnosis*
  • Atrial Fibrillation / physiopathology
  • Atrial Fibrillation / surgery*
  • Drug Administration Schedule
  • Electrocardiography
  • Electrophysiologic Techniques, Cardiac*
  • Female
  • Humans
  • Infusions, Intravenous
  • Injections, Intravenous
  • Isoproterenol* / administration & dosage
  • Male
  • Middle Aged
  • Patient Selection
  • Predictive Value of Tests
  • Prospective Studies
  • Pulmonary Veins / physiopathology
  • Pulmonary Veins / surgery*
  • Recurrence
  • Reoperation
  • Texas
  • Treatment Outcome

Substances

  • Adenosine
  • Isoproterenol